Minjuvi

Land: Den Europæiske Union

Sprog: rumænsk

Kilde: EMA (European Medicines Agency)

Aktiv bestanddel:

Tafasitamab

Tilgængelig fra:

Incyte Biosciences Distribution B.V.

ATC-kode:

L01FX12

INN (International Name):

tafasitamab

Terapeutisk gruppe:

Agenți antineoplazici

Terapeutisk område:

Lymphoma, Large B-Cell, Diffuse

Terapeutiske indikationer:

Minjuvi is indicated in combination with lenalidomide followed by Minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).

Produkt oversigt:

Revision: 4

Autorisation status:

Autorizat

Autorisation dato:

2021-08-26

Indlægsseddel

The website encountered an unexpected error. Try again later.

Produktets egenskaber

The website encountered an unexpected error. Try again later.